Drug intelligence / Profile preview

EYP971

Development stage: Preclinical
Lead developer: ENYO Pharma
Modality: Small Molecules

Overview

EYP971 is a preclinical-stage small molecule drug candidate under development by ENYO Pharma. While the specific biological target and therapeutic indications remain undisclosed as of early 2024, the compound is part of ENYO Pharma's pipeline, which generally focuses on metabolic and infectious diseases. The company utilizes a proprietary drug discovery platform that identifies novel therapeutic targets by mimicking the strategies viruses use to modulate host cell functions.

Beyond the preview

Go deeper on EYP971.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EYP971.

Explore the full profile